Autoantibody predictors of gastrointestinal symptoms in systemic sclerosis

Rheumatology (Oxford). 2022 Feb 2;61(2):781-786. doi: 10.1093/rheumatology/keab395.

Abstract

Objectives: To assess the prevalence and burden of SSc-related gastrointestinal dysfunction (SSc-GI) and to evaluate associations with demographic, clinical and serological characteristics.

Methods: Patients completed the UCLA SCTC GIT 2.0 questionnaire for SSc-GI disease to assess the burden of GI disease across multiple functional and psychological domains. Questionnaire scores were assessed using non-parametric and quantile regression analyses.

Results: Our cohort included 526 patients with SSc, with a typical distribution of disease-associated autoantibodies (ACA, ARA, ATA, PM-Scl, U1RNP, U3RNP). We demonstrated associations between hallmark antibodies and the domain-specific burden of GI disease. In particular, ACA, ARA and ENA-negative demonstrated increased SSc-GI disease burden, while PM-Scl conferred relative protection. In a distributional analysis, associations with autoantibodies were particularly marked in those with the highest burden of GI disease.

Conclusion: There is a significant burden of SSc-GI disease in patients with SSc; reflux and bloating symptoms are most prominent. SSc hallmark antibodies may predict increased risk of SSc-GI disease, in particular ACA and ARA, while PM-Scl may be protective.

Keywords: autoantibody; gastrointestinal; outcome; patient-reported outcome; scleroderma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Antinuclear / immunology
  • Autoantibodies / immunology*
  • Female
  • Gastrointestinal Diseases / etiology*
  • Gastrointestinal Diseases / immunology
  • Humans
  • Male
  • Middle Aged
  • Regression Analysis
  • Scleroderma, Systemic / complications
  • Scleroderma, Systemic / immunology*
  • Scleroderma, Systemic / pathology
  • Statistics, Nonparametric
  • Surveys and Questionnaires

Substances

  • Antibodies, Antinuclear
  • Autoantibodies